I Stock 983596306

Decentralized Clinical Trials (DCTs) aim at controlling costs, improve recruitment and retention, and increase patient diversity, all while maintaining patient-centricity activities, safety, and quality and integrity of data.

Decentralized Clinical Trials.

Reducing the burden of participating in clinical research.

PRA recognizes that we can transform and improve medical product development and research through Decentralized Clinical Trials (DCTs). It is our goal to exhibit leadership and excellence in the field of clinical research by increasing the implementation and scaling of end-to-end, customized DCTs around the world that fit the needs of patients and sponsors.

The Global Center for Excellence in for Decentralized Clinical Trials operates in partnership with all centers, therapeutic areas and functional units of PRA— from medical and regulatory to legal and quality control. This Center is the convergence of technology and clinical research, made possible by our adoption and expert use of fit-for-purpose Digital Health Technologies (DHTs).

PRA's Key DCT Differentiators:

  • Delivering customized, DCT-driven services in multiple therapeutic areas, in all phases, globally during the last 5 years.
  • Utilizing cutting edge technology to broaden the reach, increase efficiency, and enhance the engagement, convenience, and retention in clinical research.
  • Applying secondary data and tools to follow up with participants and leverage DCTs as a care option.
  • Collecting a diverse body of clinical research experts who deliver end-to-end solutions, specifically designed to each client’s needs.
  • Deploying customized patient-centric approaches supported by our concierge decentralized coordinating center
  • Implementing DCTs as a clinical research as a care option (CRAACO) for patients to leverage and unify DCTs and the standard health care systems, offering enhanced health care options to patients—they reduce the burden of research on patients while increasing study inclusion
Rodriguez Chavez Isaac copy

"The evolution of technology has given us greater opportunities to improve lives. Leveraging digital health to conduct fully decentralized trials and hybrid trials not only reduces the burden of research on the patient, but also improves the science by reaching more diverse patient populations."

Isaac Rodriguez-Chavez, SVP, Scientific & Clinical Affairs for Decentralized Clinical Trials

What Are Decentralized Clinical Trials?

DCTs bring clinical development to patients where they already are--in their own homes, on their own devices, on their own time. Through intuitive digital tools, DCTs also make study startup, patient recruitment and retention, and protocol compliance easier for patients and sponsors alike.

Medication Adherence Rates

Acceleration of Patient Enrollment Timeline

ePro Rates for Primary endpoint

Discover more about DCTs

What are Digital Health Technologies?

Digital Health Technologies (DHTs) are the instruments that allow us to successfully perform Decentralized Clinical Trials, from computing platforms and reliable connectivity tools to proprietary software, data sets, and repurposed everyday hardware (e.g. smartphones, tablets, and sensors).

Learn more about our Mobile Health Platform
Maria harrison dct

"Our goal has always been to bring people closer to care through research. By properly implementing the technological tools available to us, we can improve both scientific progress in treatments and the daily lives of our patients."

Maria Harrison, SVP, DCT Ops and Real World Solutions

What are the Benefits of DCTs?

Traditional clinical trials are historically impacted by seemingly insurmountable factors:

  • $2-3B in cost
  • Only 10-13% of minorities participate
  • High dropout rates of 20-40%
  • 80% of trails fail to meet enrollment timelines
  • Barriers of participation based on geographic location and/or socioeconomic status

Decentralized Clinical Trials potentially lower costs, increase the efficiency of clinical research, and maintain data quality and integrity while ensuring patient safety. DCTs are also integral to implementing CRAACO (Clinical Research as a Care Option) a reality—they reduce the burden of research on patients while increasing study inclusion.

Commitment to Patients

DCTs offer the following benefits to patients:

  • Patient Centricity – Participation in clinical trials from the environments where they live (e.g. their homes, towns, rural communities, and cities)
  • Population Diversity – Access to an unlimited geographical footprint, resulting in a more diverse patient population
  • Patient Retention – Decreased burden for both patients and caregivers would contribute to improved retention

Benefits to Industry

  • Additional Data – Allowing for the efficient collection of real-world data continuously or more frequently from patients over time, thus enabling the ability to mitigate risk in real-time.
  • Reducing Data Variability - DCTs offer an opportunity for data collection directly from the source and in real-time. This advantage reduces the likelihood of missing data and its variability.
  • Central Monitoring –Eliminating the need for in person audits and inspections at physical sites by allowing data to be seen from a central location and in real-time

In addition to these benefits, investigators will also be able to expand the number of simultaneous trials they can conduct as well as pave a pathway to industry progression. Biopharmaceutical companies can incrementally shift from more conservative and traditional practices to adopting more progressive approaches through digital technologies.

PRA is uniquely positioned to leverage state-of-the-art technology and our global resources in order to move clinical research into the future.

Learn more about our DCT capabilities

Read more

Learn more about the kinds of work PRA is doing related to Decentralized Clinical Trials

White Papers and Resources

View all


Thought Leadership and Insights

View all

Explore related content and topics